MeCure Industries Plc (NGX: MECURE), a pharmaceutical manufacturer in Nigeria has released its audited financial statements for the year ended December 31, 2025.
This is announced alongside a corporate actions bulletin on NGX proposing a dividend of ₦0.32 per 50 kobo ordinary share, more than double the ₦0.15 paid for 2024.
MeCure delivered robust growth, despite challenges such as inflation, forex volatility, and rising production costs in
Revenue climbed 69% to ₦77.693 billion from ₦46.027 billion in 2024, fueled by higher volumes, strategic pricing, and strong sales in acute medicines (₦42.57 billion), OTC products, supplements, and chronic therapies.
Gross Profit rose 79% to approximately ₦26.51 billion.
Operating Profit nearly doubled (+98%) to ₦16.425 billion.
Profit Before Tax increased 140% to around ₦7.93 billion.
Profit After Tax (PAT) surged 177% to ₦6.463 billion from ₦2.329 billion.
Basic Earnings Per Share (EPS) jumped to ₦1.62 (from ₦0.58).
Total Assets expanded 49% to ₦81.96 billion, reflecting heavy investments in capacity and infrastructure.
Shareholders’ Funds grew 42% to ₦19.82 billion.
The company maintained solid liquidity, with cash and equivalents rising sharply, while strategic borrowings supported expansion without excessive leverage.
In light of this, the Board has recommended a dividend of ₦0.32 per 50 kobo ordinary share. This represents a payout ratio of approximately 20% of PAT, balancing shareholder rewards with reinvestment needs.
Key dates include:
Qualification Date: Thursday, April 23, 2026 at COB
-Register Closure: Friday, April 24, 2026, to Thursday, April 30, 2026.
Payment dates will be announced following the Annual General Meeting (AGM).
Administrator and Writer
